FLUNARIZINE (10 AND 20 MG) IV VERSUS PLACEBO IN THE TREATMENT OF ACUTE MIGRAINE ATTACKS - A MULTICENTER DOUBLE-BLIND-STUDY

被引：23

作者：

PFAFFENRATH, V ^{[1
]}

OESTREICH, W ^{[1
]}

HAASE, W ^{[1
]}

机构：

[1] JANSSEN GMBH,DEPT MED DEV,W-4040 NEUSS 21,GERMANY

来源：

CEPHALALGIA | 1990年 / 10卷 / 02期

关键词：

Acute migraine attacks; drug trial; flunarizine i.v; placebo;

D O I：

10.1046/j.1468-2982.1990.1002077.x

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

In a multi-centre, randomized double-blind study, the effect and tolerance of 10 and 20 mg flunarizine i.v. versus placebo was tested on 102 migraineurs with acute migraine attacks with and/or without aura. Thirty-seven patients received 10 mg flunarizine, 32 received 20 mg and 33 received placebo. The groups were comparable. Response to treatment was defined as pain reduction of at least 50% within 60 min on a visual analogue scale after i.v. drug administration. This effect was noted on 59.4% with 20 mg flunarizine, on 24.3% with 10 mg flunarizine and on 30.3% with placebo. The tolerance of flunarizine i.v. was similar to placebo. Blood pressure and pulse rate were not affected by flunarizine. All in all, 20 mg flunarizine i.v. appeared to be a suitable alternative for treatment of acute migraine attacks. © 1990, International Headache Society. All rights reserved.

引用

页码：77 / 81

页数：5

共 3 条

[1]

Soyka D., Taneri Z., Oestreich W., Schmidt R., Flunarizine i.v. in the acute treatment of common or classical migraine attacks - a placebo controlled double blind trial, Headache, 29, pp. 21-27, (1989)

[2]

De Rood M., Vandesteene R., Gasparini R., Van Peer A., Woestenborghs R., Heykants J., Geets T., De Beukelaar F., Preliminary study on intravenous pharmakokinetics of flunarizine (0.1 mg/kg) in man, Janssen Data on file

[3]

Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain, Headache Classification Committee of the International Headache Society, 8, pp. 1-96, (1988)

← 1 →